文献速递血栓与止血

FVIII活性预测血友病A大鼠出血风险

FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.
PubMed 文献 · J Thromb Haemost · 2020-04-16

本研究在血友病A大鼠模型中,通过AAV介导的基因转移或多次静脉注射人B结构域缺失FVIII蛋白进行干预。观察12周后发现两种方法均显著减少出血并增加无出血动物比例,但部分动物产生抑制性抗体。模型分析预测,循环FVIII活性为4.8或10 IU/dL时,分别可降低出血风险90%或95%。

要点

  • AAV基因转移和FVIII蛋白注射均显著减少血友病A大鼠出血。
  • 20%至37%的治疗动物产生抗FVIII抑制性抗体,类似患者。
  • 预测FVIII活性4.8或10 IU/dL分别降低出血风险90%或95%。

核心结论

  • FVIII活性水平可预测血友病A大鼠的出血风险,4.8或10 IU/dL分别降低风险90%或95%。

研究设计与样本

  • 在血友病A大鼠模型中,通过AAV介导基因转移或多次静脉注射人B结构域缺失FVIII蛋白,观察12周。

主要发现

  • AAV组无出血动物比例43% vs 对照组0%,注射组75% vs 对照组8%。
  • 两种方法均显著减少每只动物出血次数。
  • 20%至37%的治疗动物产生抗FVIII抑制性抗体。
  • 抑制性抗体仅在AAV预防中阻碍出血减少的临床改善。

关键数值与推荐

  • 预测FVIII活性4.8 IU/dL(0.048 IU/mL)降低出血风险90%。
  • 预测FVIII活性10 IU/dL(0.1 IU/mL)降低出血风险95%。

临床怎么用

  • 血友病A大鼠模型可用于FVIII预防研究,指导优化患者治疗。
  • 监测FVIII活性有助于评估出血风险。

局限性

  • 研究为大鼠模型,结果需在患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prophylactic replacement therapy in hemophilia A (HA) patients does not adequately prevent bleeds and arthropathic complications. A more refined understanding of the relationship between coagulation factor VIII (FVIII) levels and bleeding risk during protein prophylaxis, or with gene therapy, is needed to improve patient care. OBJECTIVES: Investigate this relationship in the HA rat, a model exhibiting spontaneous bleeds and development of arthropathy similar to HA patients. METHODS: Human B domain-deleted FVIII was delivered to HA rats via adeno-associated virus (AAV)-mediated gene transfer or multiple intravenous protein injections. RESULTS AND CONCLUSIONS: After 12 weeks of observation, both approaches significantly reduced bleeds per animal and increased the proportion of bleed-free animals compared with controls (43% vs 0%, respectively [AAV]; 75% vs 8%, respectively [injection]). Both approaches resulted in an anti-FVIII inhibitory response in 20% to 37% of treated animals, similar to HA patients. Inhibitory antibodies were refractory to clinical improvement (reduction of bleeds) only in the AAV-based prophylaxis. An integrated model-based analysis of data on FVIII exposure and bleeding events was performed. This predicted the bleeding risk at any given circulating FVIII activity. Specifically, 4.8 or 10 IU/dL FVIII (0.048 and 0.1 IU/mL, respectively) were predicted to reduce bleeding risk by 90% or 95%, respectively, compared with untreated controls. Our data establish the utility of the HA rat model in FVIII prophylaxis studies and describe how FVIII activity affects bleeding risk in this setting. These enable further studies on FVIII prophylaxis focusing on disease complications for an optimized treatment of HA patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lövgren KM, Larsen MS, Zintner SM, et al. FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats. J Thromb Haemost. 2020. PMID: 32196903. doi:10.1111/jth.14804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。